(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, ...

Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...

A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

ECTRIMS and EBMT said stem cell transplant can be considered for some with RRMS, such as those who are younger and have less severe disease.

Jan 28 (Reuters) - The U.S. FDA has approved Novo Nordisk's (NOVOb.CO), opens new tab Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart ...

Intranasal foralumab can modulate a number of immune cell types in people with non-active SPMS, developer Tiziana Life ...

Novo Nordisk is conducting a different study to understand how and why semgalutide seems to reduce the progression of kidney disease, said Stephen Gough, global chief medical officer and senior ...

Joanne Slavin, a food scientist and former member of the U.S. Dietary Guidelines for Americans advisory committee weighs in ...